Serge Belanger

487 total citations
14 papers, 255 citations indexed

About

Serge Belanger is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Physiology. According to data from OpenAlex, Serge Belanger has authored 14 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cellular and Molecular Neuroscience, 12 papers in Molecular Biology and 3 papers in Physiology. Recurrent topics in Serge Belanger's work include Neuropeptides and Animal Physiology (13 papers), Receptor Mechanisms and Signaling (11 papers) and Pharmacological Receptor Mechanisms and Effects (8 papers). Serge Belanger is often cited by papers focused on Neuropeptides and Animal Physiology (13 papers), Receptor Mechanisms and Signaling (11 papers) and Pharmacological Receptor Mechanisms and Effects (8 papers). Serge Belanger collaborates with scholars based in United States and Canada. Serge Belanger's co-authors include Rémi Quirion, Robert N. DeHaven, Roland E. Dolle, W Ma, J.‐G. Chabot, Joel Cassel, Thomas M. Graczyk, Bertrand Le Bourdonnec, Diane L. DeHaven‐Hudkins and Patrick Little and has published in prestigious journals such as Neuroscience, Journal of Medicinal Chemistry and European Journal of Neuroscience.

In The Last Decade

Serge Belanger

14 papers receiving 252 citations

Peers

Countries citing papers authored by Serge Belanger

Since Specialization

Citations

This map shows the geographic impact of Serge Belanger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serge Belanger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serge Belanger more than expected).

Fields of papers citing papers by Serge Belanger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serge Belanger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serge Belanger. The network helps show where Serge Belanger may publish in the future.

Co-authorship network of co-authors of Serge Belanger

This figure shows the co-authorship network connecting the top 25 collaborators of Serge Belanger. A scholar is included among the top collaborators of Serge Belanger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serge Belanger. Serge Belanger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as μ opioid receptor antagonists with improved opioid receptor selectivity profiles 2008 ·Bioorganic & Medicinal Chemistry Letters ·Bertrand Le Bourdonnec, (unknown), Serge Belanger, (unknown), (unknown), Joel Cassel, Timothy J. O’Neill, Patrick Little, Robert N. DeHaven, Diane L. DeHaven‐Hudkins, Roland E. Dolle	4
2	Further studies of tyrosine surrogates in opioid receptor peptide ligands 2007 ·Bioorganic & Medicinal Chemistry Letters ·Roland E. Dolle, (unknown), Blanca Martínez‐Teipel, Serge Belanger, Thomas M. Graczyk, Robert N. DeHaven	5
3	Novel malonamide derivatives as potent κ opioid receptor agonists 2007 ·Bioorganic & Medicinal Chemistry Letters ·Guo‐Hua Chu, Minghua Gu, Joel Cassel, Serge Belanger, Thomas M. Graczyk, Robert N. DeHaven, (unknown), Michael Koblish, Patrick Little, Diane L. DeHaven‐Hudkins, Roland E. Dolle	24
4	Elucidation of the Bioactive Conformation of the N-Substituted trans-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine Class of μ-Opioid Receptor Antagonists 2006 ·Journal of Medicinal Chemistry ·Bertrand Le Bourdonnec, Catherine Goodman, (unknown), (unknown), Thomas M. Graczyk, Serge Belanger, Torsten Herbertz, Glenn P. A. Yap, Robert N. DeHaven, Roland E. Dolle	19
5	Synthesis and Pharmacological Evaluation of Novel Octahydro-1H-pyrido[1,2-a]pyrazine as μ-Opioid Receptor Antagonists 2006 ·Journal of Medicinal Chemistry ·Bertrand Le Bourdonnec, Catherine Goodman, Thomas M. Graczyk, Serge Belanger, (unknown), Robert N. DeHaven, Roland E. Dolle	16
6	Novel phenylamino acetamide derivatives as potent and selective κ opioid receptor agonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·Guo‐Hua Chu, Minghua Gu, Joel Cassel, Serge Belanger, (unknown), Robert N. DeHaven, (unknown), (unknown), Patrick Little, Diane L. DeHaven‐Hudkins, Roland E. Dolle	7
7	Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2,3-dihydrobenzofuran-based constraints 2005 ·Bioorganic & Medicinal Chemistry Letters ·Guo‐Hua Chu, Minghua Gu, Joel Cassel, Serge Belanger, Thomas M. Graczyk, Robert N. DeHaven, (unknown), (unknown), Patrick Little, Diane L. DeHaven‐Hudkins, Roland E. Dolle	21
8	Synthesis and structure–activity relationships of a new series of 2α-substituted trans-4,5-dimethyl-4-(3-hydroxyphenyl)piperidine as μ-selective opioid antagonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·Bertrand Le Bourdonnec, Catherine Goodman, (unknown), (unknown), Thomas M. Graczyk, Serge Belanger, Robert N. DeHaven, Roland E. Dolle	2
9	Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity 2005 ·Bioorganic & Medicinal Chemistry Letters ·Bertrand Le Bourdonnec, (unknown), (unknown), Roberta Susnow, Joel Cassel, Serge Belanger, (unknown), Robert N. DeHaven, Diane L. DeHaven‐Hudkins, Roland E. Dolle	11
10	(4-Carboxamido)phenylalanine is a surrogate for tyrosine in opioid receptor peptide ligands 2004 ·Bioorganic & Medicinal Chemistry Letters ·Roland E. Dolle, (unknown), Blanca Martínez‐Teipel, Serge Belanger, Joel Cassel, (unknown), Thomas M. Graczyk, Robert N. DeHaven	21
11	Azepinone as a conformational constraint in the design of κ-opioid receptor agonists 2004 ·Bioorganic & Medicinal Chemistry Letters ·Paul A. Tuthill, (unknown), (unknown), Joel Cassel, Serge Belanger, Robert N. DeHaven, Michael Koblish, Susan L. Gottshall, Patrick Little, Diane L. DeHaven‐Hudkins, Roland E. Dolle	16
12	trans -3,4-Dimethyl-4-(3-carboxamidophenyl)piperidines: A novel class of μ-Selective opioid antagonists 2003 ·Bioorganic & Medicinal Chemistry Letters ·Bertrand Le Bourdonnec, Serge Belanger, Joel Cassel, (unknown), Robert N. DeHaven, Roland E. Dolle	23
13	Expression of calcitonin gene-related peptide, substance P and protein kinase C in cultured dorsal root ganglion neurons following chronic exposure to mu, delta and kappa opiates 2002 ·Neuroscience ·Serge Belanger, W Ma, J.‐G. Chabot, Rémi Quirion	70
14	Effects of amyloid peptides on cell viability and expression of neuropeptides in cultured rat dorsal root ganglion neurons: a role for free radicals and protein kinase C 2001 ·European Journal of Neuroscience ·Weiya Ma, Wenhua Zheng, Serge Belanger, Satyabrata Kar, Rémi Quirion	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact